Target Information

Target General Infomation
Target ID
T67022
Former ID
TTDR00960
Target Name
Caspase
Target Type
Clinical Trial
Disease Cancer [ICD9: 140-229; ICD10: C00-C96]
Cardiovascular disorder [ICD10: I00-I99]
BioChemical Class
Peptidase
Target Validation
T67022
EC Number
EC 3.4.22.-
Drugs and Mode of Action
Drug(s) NCX-1000 Drug Info Phase 2 Cardiovascular disorder [521941]
ALS-769 Drug Info Terminated Cancer [548378]
Inhibitor Ac-DEVD-CHO Drug Info [530969]
IDN-1965 Drug Info [535873]
Isoquinoline-1,3,4(2H)-trione Drug Info [528057]
Inducer ALS-769 Drug Info [548379]
Modulator NCX-1000 Drug Info [527200]
References
Ref 521941ClinicalTrials.gov (NCT00414869) Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure. U.S. National Institutes of Health.
Ref 548378Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025089)
Ref 527200Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br J Pharmacol. 2004 Sep;143(1):33-42.
Ref 528057J Med Chem. 2006 Mar 9;49(5):1613-23.Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.
Ref 530969Eur J Med Chem. 2010 Sep;45(9):3858-63. Epub 2010 May 24.Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study.
Ref 535873Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation. 2003 Dec 16;108(24):3036-41. Epub 2003 Nov 24.
Ref 548379Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025089)

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.